Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT06593041
Recruiting Observational

ROLE of PLATELETS in the PATHOPHYSIOLOGY of SYSTEMIC LUPUS

NCT06593041 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Strasbourg, France
Phase
Observational
Started
2024-01-09
Last updated
2024-09-19

Condition(s) studied

Systemic Lupus ErythematosusSystemic Scleroderma MeetingANCA VasculitisInflammatory MyositisGougerot-Sjögren SyndromeRheumatoid Arthritis

Study summary

Blood platelets, well known for their role in hemostasis, are abnormally activated in patients suffering from systemic lupus erythematosus (SLE), but also from other immunomediated diseases (scleroderma, vasculitis, myositis, Gougerot-Sjögren's and rheumatoid arthritis) in cases of high disease activity. Once activated, platelets express adhesion molecules such as P-selectin on their surface, enabling them to interact physically with immune cells. In a recent work, we identified that activated platelets from lupus patients interact with regulatory T cells and block their regulatory function, thus participating in the deregulated activation of the immune system in SLE. In addition, inhibition of platelet-immune cell interactions by an anti-P-selectin antibody improved LES symptoms in two mouse models.

The aim of this work is to investigate other potential platelet-immune cell interactions in patients with SLE, in comparison with other autoimmune diseases (systemic scleroderma, ANCA vasculitides, inflammatory myositis, Gougerot-Sjögren syndrome and rheumatoid arthritis).

This study could lead to a better understanding of the role of platelets in the pathophysiology of autoimmune diseases, identify new biomarkers of activity, and assess the potential of new therapeutic avenues in these diseases, such as platelet targeting.

Eligibility

Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: * Patients between 18 and 70 years of age * Patient affiliated to a health insurance scheme (beneficiary or beneficiary's beneficiary) * Patient able to understand the aims and risks of research * Patient having signed and dated an informed consent form * Patient for whom the diagnosis of at least one of the following pathologies has been confirmed: * Systemic lupus erythematosus meeting ACR/EULAR 20195 classification criteria. * Systemic scleroderma meeting ACR/EULAR 20136 classification criteria. * ANCA vasculitis according to EULAR/ACR 2022.7-9 classification criteria. * Inflammatory myositis according to EULAR/ACR 201710 classification criteria. * Gougerot-Sjögren syndrome according to EULAR/ACR 2016 classification criteria11. * Rheumatoid arthritis according to ACR/EULAR 201012 classification criteria. Exclusion Criteria: * Patient in exclusion period (determined by a previous or current study) * Inability to give patient informed consent (patient in emergency or immediate life-threatening situation) * Patient under court protection * Patient under guardianship or curatorship

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Hopitaux Universitaires de Strasbourg - Hopital de Hautepierre - Service de rhumatologie Strasbourg France Recruiting

More University Hospital, Strasbourg, France trials in France

Cefazolin Antibiotic Prophylaxis in Ventricular Shunt Surgery: Determination of Cerebrospinal Fluid Concentration During Valve Implantation Recruiting
Late-term Abortions Between 14 and 16 Weeks of Gestation: Comparison of Hemorrhagic Risks in Surgical vs. Medical Abortions Recruiting
Single Arm, Monocentric, Pilot Feasibility Study on an Interactive Virtual Reality Program in 20 Complex In-clinic Palliative Care Patients Starting soon
Combined Genome and RNA Sequencing for Genetic Diagnosis of Parkinsonism Recruiting
Placental Learning Model for Neurovascular Microsurgery for the Management of Intracranial Aneurysms Recruiting

Other trials for the same condition

Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension). Recruiting
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis. Recruiting
A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus Recruiting
Neutrophil Extracellular Traps in Different Forms of Systemic Sclerosis Recruiting
Efficacy of a Sequential Treatment Strategy in Rheumatoid Arthritis Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06593041 on ClinicalTrials.gov ↗ ← All trials in France